Search

OncoKB®, a precision oncology knowledge database developed by MSK researchers and physicians, has received partial recognition status from the US Food and Drug Administration (FDA).

… Thursday, October 7, 2021 OncoKB® , a comprehensive precision oncology knowledge database developed by researchers and physicians at Memorial Sloan Kettering Cancer Center, today received partial recognition status from the US Food and Drug Administration (FDA). It is the first database of somatic variants

New MSK research discovers a new approach that could prevent chemotherapy-related leukemia; shows how monoclonal antibodies can turn neutrophils into cancer killers; helps develop sensitive CAR T cells that target CD70 antigen to destroy cancer cells; and uses single-cell studies to yield new clues about a rare, aggressive pediatric sarcoma.

… Friday, March 20, 2026   New research from Memorial Sloan Kettering Cancer Center (MSK) discovers a new approach that could prevent chemotherapy-related leukemia; shows how monoclonal antibodies can turn neutrophils into cancer killers; helps develop sensitive CAR T cells that target CD70 antigen to

The initial results of an ongoing study show that a liquid biopsy has advantages over a tissue biopsy for people with lung cancer.

… Wednesday, November 28, 2018 Summary For people with lung cancer , a blood test known as a liquid biopsy can be a useful tool for guiding treatment decisions, according to a new study from researchers at Memorial Sloan Kettering, the University of Sydney, and a biotech company called Resolution Bioscience

Maria Jasin’s discoveries have led to concrete advances in patient care. The targeted medicines called PARP inhibitors, for example, are based on knowledge gained from her work.

… Saturday, January 1, 2022 By Matt Tontonoz Maria Jasin’s discoveries have led to concrete advances in patient care. The targeted medicines called PARP inhibitors, for example, are based on knowledge gained from her work. These drugs take advantage of the fact that tumors with a BRCA mutation are less

MSK researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting.Highlights included breakthroughs for patients with advanced gastric cancer, lung cancer, Lynch syndrome-related cancer and salivary gland cancer. Additionally, the first-ever CAR T cell trial for patients with light chain amyloidosis is showing promising results.

… Tuesday, June 3, 2025 Memorial Sloan Kettering Cancer Center (MSK) researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting held May 30 to June 3, 2025, in Chicago. Highlights included breakthroughs for patients with advanced

Dimiter Tassev, a member of Gerstner Sloan Kettering's inaugural class, has completed all his degree requirements and will receive his PhD in May.

… Tuesday, March 1, 2011 Dimiter Tassev, a member of Gerstner Sloan Kettering’s inaugural class, has completed all his degree requirements and will receive his PhD in May. Dr. Tassev did his thesis work in the laboratory of Nai-Kong Cheung . “My thesis project originally came about through my own personal

Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.

… Thursday, May 2, 2013 Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers. This effort will focus on co-development of a new Foundation Medicine molecular

Annually, Gerstner Sloan Kettering recognizes student research through fellowship awards with the Grayer Fellowships, the Catell Fellowship, the Olayan Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowship.

… Friday, August 26, 2016 Gerstner Sloan Kettering student stipends are supported by a variety of sources including philanthropic fellowships. Annually, GSK awards fellowships to two third-year students and six second-year students based on academic excellence. Grayer Fellows Third-year students Jacob

New MSK research shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental antibody that shows promise against metastatic cancer; sheds light on the origins of ERG-driven prostate cancer; and finds Dupilumab is a successful agent to treat skin toxicities related to antibody-drug conjugates.

… Thursday, September 4, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental antibody that shows promise against metastatic cancer; sheds light on the

MSK’s Kathryn Beal presents new findings on combining radiation with immunotherapy for brain cancer.

… Tuesday, September 27, 2016 Summary In this Q&A, MSK radiation oncologist Kathryn Beal discusses recent advances in treating brain cancer with a combination of radiation and immunotherapy. This week in Boston, radiation oncologists from around the world are attending the annual meeting of the American